Investor Relations
Itamar Medical is a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders. We commercialize a digital healthcare platform to facilitate the continuum of care for effective sleep apnea management with a focus on the core sleep, cardiology and direct to consumer markets.
Our prescription WatchPAT family of products, which utilizes the PAT signal, is designed to enable patients suspected to have sleep related breathing disorders to easily conduct sleep apnea tests in the comfort of their homes in accordance with a physician’s instructions, as authorized by qualified medical personnel while delivering the treating physicians with comprehensive, accurate and reliable results to aid in the diagnosis of sleep apnea.
Enables Patient Smartphone App to Collect Subjective Data at Time of Test Designed to Improve the Quality and Efficiency of Home Sleep Diagnostics CAESAREA, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company
CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its
– First Quarter 2021 Revenues Increase 43% to $12.0 Million – – U.S. WatchPAT™ Revenues Increase 38% to $8.4 Million – – Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT – CAESAREA, Israel, May 19, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd.
CAESAREA, Israel, May 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced its WatchPAT® technology was highlighted in
CAESAREA, Israel, May 05, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results
Significant Majority Expect Home Sleep Apnea Test Usage to Expand and in-lab Usage to Decline Most Clinicians Expect More than Half of Future Sleep Diagnostics W ill B e At-Home Tests Results Indicate Vast Majority of Participants Use HSAT in Their Practices Today CAESAREA, Israel, April 12, 2021
May 19, 2021 at 8:00 AM EDT
May 5, 2021 at 10:47 AM EDT
Mar 4, 2021 at 10:30 AM EST
Mar 2, 2021 at 8:00 AM EST
